Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics furnished an 8-K announcing that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The company also updated its investor presentation the same day.
The results press release is furnished under Item 2.02, and the updated presentation is furnished under Item 7.01. These materials are available as Exhibits 99.1 and 99.2. The information in Items 2.02 and 7.01 is being furnished and is not deemed filed or incorporated by reference except as expressly stated in future filings.
Fulgent Genetics (FLGT) — Form 4: The company’s Chief Scientific Officer reported a tax‑withholding transaction on 10/26/2025. 1,642 shares of common stock were withheld (code F) to cover taxes upon vesting of restricted stock units related to the November 7, 2022 merger. The withholding was recorded at a price of $23.74 per share.
After this administrative transaction, the reporting person beneficially owns 955,443 shares of FLGT common stock, held directly.
Fulgent Genetics (FLGT) — Form 4 insider transaction: the company’s CFO and Treasurer reported a tax-related share withholding tied to equity vesting. On 10/26/2025, 2,743 shares of common stock were withheld under transaction code F at a price of $23.74 to satisfy tax obligations upon the vesting of restricted stock units assumed in the November 7, 2022 merger agreement.
Following this administrative transaction, the reporting person beneficially owned 334,118 shares directly. This filing reflects routine tax withholding associated with stock-based compensation rather than an open-market purchase or sale.
Fulgent Genetics (FLGT) reported an insider transaction by its President and COO. On 10/26/2025, 4,353 shares of common stock were withheld at $23.74 per share to cover taxes upon the vesting of previously assumed restricted stock units (Transaction Code F).
After the transaction, the reporting person beneficially owned 359,768 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust. The filing notes the reporting person disclaims beneficial interest in the trust except for any pecuniary interest.
Fulgent Genetics reported preliminary clinical data from its ongoing phase 2 study of FID-007 in combination with cetuximab for ≤ 2nd line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma. The company furnished a press release with these details as Exhibit 99.1.
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported the sale of 1,063 shares of the issuer's common stock on 09/03/2025. The filing states the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units originally granted on 02/28/2022. The shares were sold in multiple transactions at prices ranging from $21.92 to $22.175, with a reported weighted-average sale price of $22.0267. Following the reported sale, the reporting person beneficially owns 957,085 shares, held directly.
Xie Jian, President and COO of Fulgent Genetics, Inc. (FLGT), reported the sale of 1,128 shares of the issuer's common stock on 09/03/2025 at a weighted-average sale price of $22.0267 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/28/2022. After the reported sale, Mr. Xie beneficially owned 364,121 shares directly and held an additional 220,816 shares indirectly through The Hsieh Family Dynasty Trust, dated January 27, 2010. The Form 4 was executed by Paul Kim as attorney-in-fact.
Paul Kim, identified as CFO and Treasurer of Fulgent Genetics, Inc. (FLGT), reported a transaction dated 09/01/2025 in which 1,131 shares of the issuer's common stock were disposed of under transaction code F at a price of $22.17 per share. The filing explains these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units originally granted on February 28, 2022. After the withholding, the reporting person beneficially owns 336,861 shares, held directly. The Form 4 is signed by Paul Kim on 09/03/2025.
Fulgent Genetics, Inc. (FLGT) filed a Form 144 notice reporting a proposed sale of 1,128 shares of common stock through Morgan Stanley Smith Barney on 09/03/2025, with an aggregate market value of $24,846.15. The filer acquired the shares as restricted stock vesting on 02/28/2022 as equity compensation (32,000 shares acquired on that date). The filing shows prior sales by the same person in August 2025 totaling 1,895 shares for gross proceeds of $40,725.28. Total shares outstanding are reported as 30,609,044.
Form 144 filed for Fulgent Genetics, Inc. (FLGT) reports a proposed sale of 1,063 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $23,414.42, listed for sale on NASDAQ and an approximate sale date of 09/03/2025. The shares were acquired by the seller as restricted stock that vested on 02/28/2022 and were granted as equity compensation for services rendered. The filer also reports two recent sales in August 2025 totaling 1,491 shares for gross proceeds of $32,042.96. The filing includes the seller's representation that they are unaware of any undisclosed material adverse information about the issuer.